For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Other Questions

Back to Help Center

If the media tubes are damaged or missing something in the packaging can we get a replacement?

Please request fresh tubes on our website (Vet Portal > Request Supplies). If you need to send cells immediately, please use the serum and saline protocol from the CSU Hemapathology Lab. (Click to read more)

What services does ImpriMed offer?

ImpriMed offers personalized medicine services to help you diagnose and treat canine lymphoma or leukemia. (Click to read more)

Why should I order ImpriMed services?

ImpriMed offers a unique precision oncology service that helps you to find the best anticancer drugs for your patients. ImpriMed directly tests a panel of commonly used anticancer drugs on your patients’ live cells in our A2LA accredited lab. In addition, we continually collect patient outcomes that are updated via regular follow-up with pet parents. As our database grows, so does the performance of our anticancer drug response predictions and your ability to develop a personalized treatment plan for each pet patient. So, when you order an ImpriMed service, you are actively contributing to our dataset and helping to improve cancer care for your patients and the ImpiMed user community.

What does PARR tell me about my patient’s specimen?

PARR, which stands for PCR for Antigen Receptor Rearrangements, is used to discriminate between lymphoma/leukemia and reactive/inflammatory conditions when cytology is equivocal. Our canine PARR assay detects the expansion of B-cell cancer clones by amplifying the VJ region of the immunoglobulin heavy chain gene (IgH) and detects the expansion of T-cell cancer clones by amplifying a region in the T-cell receptor gamma chain gene.

What is the successful prediction rate for this test?

Positive predictive values for our AI-based drug response predictions are 80% or higher.